Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQ: CRVS · Real-Time Price · USD
3.630
-0.030 (-0.82%)
At close: Apr 25, 2025, 4:00 PM
3.630
0.00 (0.00%)
After-hours: Apr 25, 2025, 7:06 PM EDT
Corvus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Corvus Pharmaceuticals stock have an average target of 15.67, with a low estimate of 11 and a high estimate of 21. The average target predicts an increase of 331.68% from the current stock price of 3.63.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 26, 2025.
Analyst Ratings
The average analyst rating for Corvus Pharmaceuticals stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 5 | 5 | 5 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $14 → $15 | Buy | Maintains | $14 → $15 | +313.22% | Mar 26, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +203.03% | Mar 26, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +203.03% | Jan 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $11 | Strong Buy | Initiates | $11 | +203.03% | Jan 2, 2025 |
| Oppenheimer | Oppenheimer | Buy Reiterates $8 → $14 | Buy | Reiterates | $8 → $14 | +285.67% | Nov 13, 2024 |
Financial Forecast
Revenue This Year
n/a
from 101.79M
Revenue Next Year
n/a
EPS This Year
-0.51
from -1.02
EPS Next Year
-0.66
from -0.51
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 10.5M | 35.9M | ||
| Avg | n/a | 2.6M | 19.9M | ||
| Low | n/a | n/a | 2.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 1,308.2% | ||
| Avg | - | - | 682.0% | ||
| Low | - | - | -7.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.45 | -0.43 | -0.34 | ||
| Avg | -0.51 | -0.66 | -0.65 | ||
| Low | -0.56 | -0.93 | -1.01 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.